LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Search

Penumbra Inc

Slēgts

SektorsVeselības aprūpe

266.7 0.85

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

265.75

Max

269.7

Galvenie mērījumi

By Trading Economics

Ienākumi

6M

45M

Pārdošana

15M

339M

P/E

Sektora vidējais

59.839

77.256

Peļņas marža

13.336

Darbinieki

4,500

EBITDA

1.9M

51M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+15.26% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-92M

8.8B

Iepriekšējā atvēršanas cena

265.85

Iepriekšējā slēgšanas cena

266.7

Ziņu noskaņojums

By Acuity

27%

73%

63 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Penumbra Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 9. nov. 21:36 UTC

Peļņas

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

2025. g. 9. nov. 21:22 UTC

Peļņas

Australia's ANZ Bank Posts 10% Drop in Annual Profit

2025. g. 10. nov. 00:00 UTC

Tirgus saruna

India Inflation Poised to Hit New Low -- Market Talk

2025. g. 9. nov. 23:47 UTC

Tirgus saruna

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

2025. g. 9. nov. 23:35 UTC

Tirgus saruna

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

2025. g. 9. nov. 21:05 UTC

Peļņas

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

2025. g. 9. nov. 21:04 UTC

Peļņas

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

2025. g. 9. nov. 21:03 UTC

Peļņas

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

2025. g. 9. nov. 20:49 UTC

Peļņas

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

2025. g. 9. nov. 20:49 UTC

Peļņas

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

2025. g. 9. nov. 20:45 UTC

Peļņas

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

2025. g. 9. nov. 20:45 UTC

Peļņas

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

2025. g. 9. nov. 20:42 UTC

Peļņas

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

2025. g. 9. nov. 20:42 UTC

Peļņas

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

2025. g. 9. nov. 20:41 UTC

Peļņas

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

2025. g. 9. nov. 20:41 UTC

Peļņas

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

2025. g. 9. nov. 20:39 UTC

Peļņas

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

2025. g. 9. nov. 20:39 UTC

Peļņas

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

2025. g. 9. nov. 20:38 UTC

Peļņas

ANZ Keeps Dividend at A$0.83 >ANZ.AU

2025. g. 9. nov. 20:38 UTC

Peļņas

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

2025. g. 9. nov. 20:38 UTC

Peļņas

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

2025. g. 8. nov. 13:10 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

2025. g. 8. nov. 03:50 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

2025. g. 8. nov. 03:41 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

2025. g. 8. nov. 03:07 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

2025. g. 7. nov. 22:36 UTC

Peļņas

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

2025. g. 7. nov. 22:22 UTC

Peļņas

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

2025. g. 7. nov. 22:03 UTC

Peļņas

Constellation Software 3Q Rev $2.95B >CSU.T

2025. g. 7. nov. 22:03 UTC

Peļņas

Constellation Software 3Q Net $210M >CSU.T

2025. g. 7. nov. 22:03 UTC

Peļņas

Constellation Software 3Q EPS $9.89 >CSU.T

Salīdzinājums

Cenas izmaiņa

Penumbra Inc Prognoze

Cenas mērķis

By TipRanks

15.26% augšup

Prognoze 12 mēnešiem

Vidējais 306.82 USD  15.26%

Augstākais 355 USD

Zemākais 266 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Penumbra Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

13 ratings

10

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

288.28 / 292.9394Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Weak Bullish Evidence

Noskaņojums

By Acuity

63 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat